

Fixed AV Delay Works Well for Most CRT Users

BY MITCHEL L. ZOLER

FROM THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION

CHICAGO – The standard, atrioventricular delay built into many cardiac resynchronization devices worked as effectively as did an automated patient-tailored delay or a delay based on a time-consuming echocardiography assessment in a randomized trial that involved nearly 1,000 patients.

“The routine use of AV [atrioventricular] optimization techniques assessed in this trial is not warranted,” Dr. Kenneth A. Ellenbogen said at the meeting. But it may help patients who don’t initially respond to cardiac resynchronization therapy (CRT), he added, although the results he reported did not assess this possibility.

The findings refuted a recommendation made in 2008 by a panel of the American Society of Echocardiography to routinely use an echo assessment to set the AV delay in patients receiving a CRT device (*J. Am. Soc. Echocardiogr.* 2008;21:191-213).

“The algorithms [for determining an optimal AV delay] made excellent sense hemodynamically, but you need a clinical trial to look at clinical outcomes,” said Dr. Ellenbogen, vice-chairman of cardiology and director of clinical cardiac electrophysiology and pacing at Virginia Commonwealth University in Richmond, Va.

“The bottom line is we can save patients an expensive and time-consuming study that really doesn’t benefit the majority of patients. The out-of-the-box settings seem to work in most patients,” he added.

A detailed echo study “is about an hour long and uses resources,” and was no better than the alternatives, commented Dr. Gordon F. Tomaselli, professor and chief of cardiology at Johns Hopkins University in Baltimore. “The key comparison of the study was do we need to do a detailed echo study on everyone to optimize the hemodynamics, and the answer was no,” he said in an interview.

The results also called into question the usefulness of a feature in all CRT devices on the U.S. market that automatically attempts to optimize the AV delay based on what the device detects as the patient’s intrinsic AV interval and baseline QRS width. In the Boston Scientific CRT unit used in the new study, this feature is called “SmartDelay.” The study results showed no significant benefit from the SmartDelay feature compared with a fixed AV delay of 120 msec for all patients.

“All the companies have their algorithms” for setting the AV delay, said Dr. Tomaselli. He also noted that while the new results showed no significant difference between the fixed delay of 120 msec and the variable delays applied by the device’s built-in programming function, several outcomes showed trends toward superiority using the built-in program.

For example, in the study’s primary outcome – the median change in left ventricular end systolic volume at 6 months after placement of the CRT device – the results showed a median 21-mL reduction in patients whose delay got set by the device’s internal program (which produced an average delay of 48 msec) and a median 15-mL reduction in patients who received a device set to the fixed, 120-msec delay. Patients who un-

derwent an echo-guided procedure to set the delay had a median reduction of 19 mL.

The SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy (SMART-AV) trial randomized and implanted 980 patients at 100 centers in the United States and Europe during May 2008–December 2009. The researchers were able to per-

form follow-up assessments on 86% of the randomized patients. The patients’ average age was 66, two-thirds were men, and more than 90% had New York Heart Association class III heart failure.

The study’s secondary outcomes analyses also showed no significant differences between the three methods used to set the AV delay for changes in left ventricular end diastolic volume, ejection fraction, 6-minute walk, quality of life, or

Effient® (prasugrel) is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: [1] patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI); [2] patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI.



Major Finding: In patients who received a cardiac resynchronization device to treat severe heart failure, three different methods for setting the atrioventricular delay – an echocardiographic assessment, a built-in program of the device, and a fixed, 120-msec delay used for all patients – produced no statistically significant differences in the change in left ventricular end systolic volume at 6 months after device placement.

Data Source: The SMART-AV trial, which randomized and implanted 980 patients at 100 centers in the United States and Europe during May 2008–December 2009.

Disclosures: The study was sponsored by Boston Scientific. Dr. Ellenbogen said that he has served as a consultant or an advisory board member to, lectured on behalf of, and/or received research grants from, Boston Scientific, Biotronik, Medtronic, St. Jude Medical, Sorin Group, Cardionet, Atlicare, EBR, Sanofi-Aventis, and Biosense Webster. Dr. Tomaselli said that he had no disclosures.

NYHA heart failure class. A series of post hoc subgroup analyses also generally showed no difference between the three methods. These included patients with ischemic or nonischemic heart failure etiology, patients with either greater or less than 30% atrial pacing, patients with or without bundle branch block, and those with a QRS duration of less than 150 msec and those with a duration of at least 150 msec.

The only subgroup that showed a differential effect was in women, who had a significantly better response to either the device-selected AV delay or an echo-guid-

ed delay compared with the fixed, 120-msec delay. In men, the three approaches had identical effects. The implications of this finding for selecting a CRT delay in women will need further study, Dr. Ellenbogen said. He also stressed the need to compare the efficacy of the three delay-setting approaches in the roughly 25% of patients who don't initially respond to their CRT device.

Concurrently with Dr. Ellenbogen's report at the meeting, the results were published online (*Circulation* 2010 Nov. 15 [doi:10.1161/circulationaha.110.992552]). ■

Effient plus aspirin (ASA) provided **STRONGER PROTECTION**

vs Plavix® (clopidogrel bisulfate) plus ASA against thrombotic cardiovascular (CV) events (including stent thrombosis)

- In the overall UA/NSTEMI population, event rates* for Effient plus ASA and Plavix plus ASA were 9.3% and 11.2%, respectively (1.9% ARR[†]; P=0.002). In the overall STEMI population, event rates for Effient plus ASA and Plavix plus ASA were 9.8% and 12.2%, respectively (2.4% ARR; P=0.02)^{1,2}
- Difference in treatments was primarily driven by a significant reduction in nonfatal myocardial infarctions (MIs), with no significant difference in CV death or nonfatal stroke¹
 - In the overall study population, approximately 40% of MIs occurred periprocedurally and were detected solely by changes in CK-MB
- 52% RRR[‡] in stent thrombosis in the all-ACS population with Effient plus ASA vs Plavix plus ASA (1.1% vs 2.2%; 1.1% ARR; P<0.0001)³
- TRITON-TIMI 38 was a head-to-head study comparing Effient (60-mg loading dose [LD], followed by 10-mg once-daily maintenance dose) plus ASA with Plavix (300-mg LD, followed by a 75-mg once-daily maintenance dose) plus ASA in 13,608 patients with ACS managed with PCI (median duration 14.5 months)
 - In TRITON-TIMI 38, the LD of Plavix was delayed relative to the placebo-controlled trials that supported its approval for ACS

For more information, please visit EffientHCP.com or Effientconferences.com.

SELECTED SAFETY, INCLUDING SIGNIFICANT BLEEDING RISK

Effient can cause significant, sometimes fatal, bleeding. In TRITON-TIMI 38, overall rates of non-CABG TIMI major or minor bleeding were significantly higher with Effient plus ASA (4.5%) compared with Plavix plus ASA (3.4%). In patients who underwent CABG (n=437), the rates of CABG-related TIMI major or minor bleeding were 14.1% with Effient plus ASA and 4.5% with Plavix plus ASA.

IMPORTANT SAFETY INFORMATION

WARNING: BLEEDING RISK

Effient® (prasugrel) can cause significant, sometimes fatal, bleeding. Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke. In patients ≥75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction [MI]) where its effect appears to be greater and its use may be considered. Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery. Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]). Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient. If possible, manage bleeding without discontinuing Effient. Discontinuing Effient, particularly in the first few weeks after acute coronary syndrome, increases the risk of subsequent cardiovascular events.

CONTRAINDICATIONS

- Effient is contraindicated in patients with active pathological bleeding, such as from a peptic ulcer or intracranial hemorrhage (ICH), or a history of transient ischemic attack (TIA) or stroke, and in patients with hypersensitivity to prasugrel or any component of the product

WARNINGS AND PRECAUTIONS

- Patients who experience a stroke or TIA while on Effient generally should have therapy discontinued. Effient should also be discontinued for active bleeding and elective surgery
- Premature discontinuation of Effient increases risk of stent thrombosis, MI, and death
- Thrombotic thrombocytopenic purpura (TTP), a rare but serious condition that can be fatal, has been reported with Effient, sometimes after a brief exposure (<2 weeks), and requires urgent treatment, including plasmapheresis

ADVERSE REACTIONS

- Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction

Please see Brief Summary of Prescribing Information on subsequent pages.

*As measured by reduction in the primary composite endpoint of CV death, nonfatal MI, or nonfatal stroke.

[†]Absolute risk reduction.

[‡]Relative risk reduction.

 **Effient**
(prasugrel) tablets